Ardelyx Inc Total Liabilities
Ardelyx Inc total liabilities. Based on the latest financial reports, Ardelyx Inc (ARDX) has total liabilities worth $426.88 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ardelyx Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ardelyx Inc (2012–2025)
Total liabilities of Ardelyx Inc from 2012 to 2025. This chart illustrates how Ardelyx Inc's total liabilities have evolved over time, based on quarterly financial data. Explore ARDX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Ardelyx Inc Competitors by Total Liabilities
The table below lists competitors of Ardelyx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cello World Limited
NSE:CELLO
|
India | Rs2.64 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥397.56 Million |
|
Anhui Landun Photoelectron Co Ltd
SHE:300862
|
China | CN¥380.07 Million |
|
African Rainbow Capital Investments Ltd
JSE:AIL
|
South Africa | ZAC2.00 Million |
|
Yangmei Chemical Co Ltd
SHG:600691
|
China | CN¥10.52 Billion |
|
Rpmglobal Holdings Ltd
AU:RUL
|
Australia | AU$48.30 Million |
|
Priortech
TA:PRTC
|
Israel | ILA123.21 Million |
|
ALPHAMAB ONCOLO.DL-000002
F:3NK
|
Germany | €386.17 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Ardelyx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ardelyx Inc asset portfolio.
Liquidity & Leverage Metrics
Ardelyx Inc Total Liabilities Ratios Explained
Ardelyx Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ardelyx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ardelyx Inc (2012–2025)
The table below shows the annual total liabilities of Ardelyx Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $334.65 Million | +27.50% |
| 2024-12-31 | $262.46 Million | +100.72% |
| 2023-12-31 | $130.76 Million | +42.54% |
| 2022-12-31 | $91.74 Million | +36.32% |
| 2021-12-31 | $67.30 Million | -10.81% |
| 2020-12-31 | $75.45 Million | +3.18% |
| 2019-12-31 | $73.13 Million | +8.31% |
| 2018-12-31 | $67.52 Million | +263.18% |
| 2017-12-31 | $18.59 Million | -6.95% |
| 2016-12-31 | $19.98 Million | +148.35% |
| 2015-12-31 | $8.04 Million | -84.74% |
| 2014-12-31 | $52.73 Million | +4.99% |
| 2013-12-31 | $50.23 Million | +28.39% |
| 2012-12-31 | $39.12 Million | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more